Bacterial Vaginosis Clinical Trial
Official title:
Efficacy of Bovhyaluronidase Azoximer on Biofilms Destruction in the Urogenital Tract of the Patients With Recurrent Bacterial Vaginosis.
Bacterial vaginosis (BV) occupies one of the leading places in the structure of the of gynecologic morbidity. This syndrome affects from 26 to 29% of women of reproductive age. Bacterial vaginosis is a non-inflammatory syndrome based on the replacement of normal lactoflora by opportunistic microorganisms. The modern concept of pathogenesis of bacterial vaginosis is the formation of biofilms, mainly Gardnerella vaginalis, on the surface of the vaginal epithelium. Associated with biofilms bacterial vaginosis is characterized by increased resistance to pathogenetic therapy, ability to evade protective mechanisms and prolonged persistence in the vaginal environment, which is manifested by an increase in the rate of recurrent and chronic course. In connection with the above described, it is relevant to study in vivo the role of drug action on biofilms in order to destroy them and, as a consequence, to increase the effectiveness of pathogenetic antibacterial therapy, reduce the frequency of BV recurrences and improve the quality of life of women. According to the local and international literature, there are various ways to affect biofilms, one of which is enzymatic destruction of the matrix. Bovgialuronidase azoximer was chosen as the study drug.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03930745 -
Suppression Of Bacterial Vaginosis (BV) [SUBVert]
|
Phase 2 | |
| Completed |
NCT02863536 -
A Study of the New Medical Device Polybactum®
|
N/A | |
| Completed |
NCT03187457 -
PreFem: "What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?"
|
N/A | |
| Recruiting |
NCT02185456 -
Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis
|
Phase 0 | |
| Completed |
NCT02150655 -
Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women
|
Phase 0 | |
| Completed |
NCT01450462 -
Vitamin D and Sexual Health
|
N/A | |
| Recruiting |
NCT01558388 -
Probiotic Versus Placebo as Adjuvant for Bacterial Vaginosis Treatment During Pregnancy
|
Phase 4 | |
| Not yet recruiting |
NCT00889356 -
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
|
Phase 3 | |
| Completed |
NCT01471457 -
Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis
|
Phase 2/Phase 3 | |
| Completed |
NCT00556179 -
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
|
Phase 4 | |
| Completed |
NCT00545181 -
Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
|
N/A | |
| Completed |
NCT02236156 -
Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)
|
Phase 3 | |
| Not yet recruiting |
NCT05434104 -
The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study
|
N/A | |
| Completed |
NCT01335373 -
Observational Program Neo-Penotran® Forte
|
N/A | |
| Completed |
NCT00752193 -
Safety and Efficacy of a Vaginally Administered Probiotic Lactobacilli Delivery System.
|
N/A | |
| Active, not recruiting |
NCT00536848 -
The Effect of Probiotics on the Immune Status, Diarrhea and Bacterial Vaginosis Cure Rate Among HIV Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT00510614 -
Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study
|
Phase 0 | |
| Suspended |
NCT00207480 -
Brief, Behavioral Intervention to Reduce Douching Among Adolescent and Young Women
|
Phase 1 | |
| Recruiting |
NCT05278130 -
Serial Screening and Treatment of Bacterial Vaginosis Trial
|
N/A | |
| Completed |
NCT02905890 -
The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis
|
Phase 4 |